Ironwood Being Split In Two: Is Move To Thwart Activist Investor Sarissa?

Move will spin out sGC assets into solo listed group while smaller Ironwood will focus on GI diseases and abdominal pain.

Spin off
Ironwood's Split Will Spin Off sGC Assets • Source: Shutterstock

Catching investors and analysts on the hop, Cambridge, Mass.-based Ironwood Pharmaceuticals Inc. unveiled plans to separate into two publicly traded groups, in a move seen at least partly motivated by an activist investor's plans to extract more value for its shareholders.

The restructuring of Ironwood will see the spinning out of its soluble guanylate cyclase (sGC) stimulator pipeline for rare disorders...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.